Patent ID: 7615528

Claim:
A method for alleviating the deleterious effects of 3-deoxyglucosone (3DG) in a patient, said 3DG being produced by the enzymatic conversion of fructose-lysine to fructose-lysine-3-phosphate, said method comprising administering to said patient an inhibitor of said enzymatic conversion of fructose-lysine to fructose-lysine-3-phosphate said inhibitor being a compound having the formula: wherein X is a divalent moiety selected from the group consisting —NR′— or —O—, R′ being selected from the group consisting of H, and linear or branched chain alkyl group (C 1 -C 4 ) and an unsubstituted or substituted aryl group (C 6 -C 10 ) or aralkyl group (C 1 -C 10 ); R is a substituent selected from the group consisting of H, an amino acid residue said amino acid including said NR′ moiety, a polyamino acid residue said polyamino acid including said NR′ moiety, a peptide chain, a linear or branched chain aliphatic group (C 1 -C 8 ), which is unsubstituted or substituted with at least one nitrogen or oxygen-containing substituent, a linear or branched chain aliphatic group (C 1 -C 8 ), which is unsubstituted or substituted with at least one nitrogen- or oxygen-containing substituent and interrupted by at least one —O—, —NH—, or —NR″— moiety, R′ being linear or branched chain alkyl(C 1 -C 6 ) and an unsubstituted or substituted aryl group C 6 -C 10 ) or aralkyl group (C 7 -C 10 ), with the proviso that when X represents —NR′—, R and R′, together with the nitrogen atom to which they are attached, may also represent a substituted or unsubstituted heterocyclic ring having from 5 to 7 ring atoms, with at least one of nitrogen and oxygen being the only heteroatoms in said ring, said aryl group (C 6 -C 10 ) or aralkyl group (C 7 -C 10 ) and said heterocyclic ring substituents being selected from the group consisting of H, alkyl(C 1 -C 6 ), halogen, CF 3 , CN, and —O-alkyl(C 1 -C 6 ); R 1 is a polyol moiety having 1 to 4 linear carbon atoms, Y is a hydroxymethylene moiety Z is selected from the group consisting of —H, —O-alkyl (C 1 -C 6 ), -halogen —CF 3 , —CN, —COOH, —OH and —SO 3 H 2 and the sterooisomers and pharmaceutically acceptable salts of said compound with inorganic acids, methane sulfonic acid, inorganic bases or organic bases.